scholarly journals The local treatment modalities in FIGO stage I‐II small‐cell carcinoma of the cervix are determined by disease stage and lymph node status

2016 ◽  
Vol 5 (6) ◽  
pp. 1108-1115 ◽  
Author(s):  
Juan Zhou ◽  
Hong‐Yi Yang ◽  
San‐Gang Wu ◽  
Zhen‐Yu He ◽  
Huan‐Xin Lin ◽  
...  
Keyword(s):  
Lymph Node ◽  
Cell Carcinoma ◽  
Small Cell Carcinoma ◽  
Local Treatment ◽  
Figo Stage ◽  
Small Cell ◽  
Stage I ◽  
Disease Stage ◽  
Treatment Modalities ◽  
Lymph Node Status

scholarly journals Postoperative adjuvant radiation improves local control in surgically treated FIGO stage I-II small cell carcinoma of the cervix

2019 ◽  
Vol 14 (1) ◽  
Author(s):  
Ting Shen ◽  
Yan-hui Jiang ◽  
Yao-yao Zou ◽  
Fang-fang Qiu ◽  
Xing-sheng Qiu ◽  
...  
Keyword(s):  
Cell Carcinoma ◽  
Small Cell Carcinoma ◽  
Local Control ◽  
Multivariable Analysis ◽  
Disease Free Survival ◽  
Figo Stage ◽  
Small Cell ◽  
Stage I ◽  
Adjuvant Radiation ◽  
Significant Prognostic Factor

Abstract Objective To determine the prognostic effect of adjuvant radiation and clinicopathological variables in surgically treated patients with small cell carcinoma of the cervix (SCCC). Methods Clinical data of SCCC patients with International Federation of Gynaecology and Obstetrics (FIGO) stage I-II underwent radical surgery from May 2000 to August 2014 at Sun Yat-sen Memorial Hospital were retrospectively reviewed. Forty-three patients with SCCC were included to this study. Chi-square test or Fisher’s exact test, Student’s t test or Mann–Whitney U test, Kaplan–Meier method and multivariate analysis of Cox proportional hazards regression were used for statistical analysis. P < 0.05 was considered to be statistically significant. Results Among 43 patients (median age, 49 years old) recruited, 25(58.1%) had stage I, 18(41.9%) had stage II disease. The 5-year overall survival (OS) rate was 39.54%, and the 5-year disease free survival (DFS) was 27.91%. Distant metastasis was the main cause of treatment failure (71.9%). Patients with adjuvant chemoradiation displayed lower rate of local recurrence than those with adjuvant chemotherapy (10.7% vs 60.0%, P < 0.0001). Multivariable analysis identified lymph node metastasis as a significant prognostic factor for both DFS and OS (P = 0.001, 0.004 respectively). Age was also an independent predictor of OS (P = 0.004). Adjuvant radiation appeared to significantly improve DFS (HR = 0.383, 95% CI, 0.185–0.791), but not OS. Conclusions Adjuvant radiotherapy could improve the local control and prolong DFS in surgically treated SCCC. However, a large prospective clinical trial is needed to confirm this.

Small cell carcinoma of the uterine cervix: a multi-institutional experience

2019 ◽  
Vol 30 (2) ◽  
pp. 174-180
Author(s):  
Junyun Li ◽  
Yi Ouyang ◽  
Yalan Tao ◽  
Ligen Wang ◽  
Mingyi Li ◽  
...  
Keyword(s):  
Overall Survival ◽  
Lymph Node ◽  
Cell Carcinoma ◽  
Small Cell Carcinoma ◽  
Uterine Cervix ◽  
Disease Free Survival ◽  
Figo Stage ◽  
Small Cell ◽  
Free Survival ◽  
Disease Free

ObjectiveSmall cell carcinoma of the uterine cervix is associated with a poor prognosis with a median overall survival that is quite low. The aim of this study was to determine the clinico-pathologic characteristics that have an impact on survival in patients with small cell carcinoma of the uterine cervix.MethodsA total of 93 patients were involved in this retrospective study. Inclusion criteria were patients diagnosed with histopathologically confirmed small cell carcinoma of the uterine cervix and then later treated at three participating centers, between June 2001 and March 2015. Those without complete available follow-up records were excluded. The endpoints of this study were disease-free survival and overall survival. Kaplan-Meier and Cox regression methods were used for analyses.ResultsThere were statistical differences in overall survival between patients in early and in advanced stages by using the 2009 International Federation of Gynecology and Obstetrics (FIGO) clinical stage. There were 75 patients with FIGO stage I to IIA (56 patients stage I, 17 patients stage IIA, and two patients stage IB or IIA because of uncertainty as to whether the fornix was involved); and 18 patients with FIGO stage IIB and above (10 patients IIB stage, five patients stage III, and three patients stage IV). Among the 76 patients who had surgery, 73 (96%) had a radical hysterectomy with pelvic lymph node dissection and three (4%) patients had a simple hysterectomy without lymph node dissection. For early-stage patients, the 5 year disease-free survival rate was 52.7% compared with 32.4% in the advanced stage group (p=0.022). The disease-free survival for the early-stage group was 64.4% compared with 36.7% in the advanced-stage group (p=0.047). For factors affecting overall survival, age at diagnosis, tumor homology, tumor size, depth of stromal invasion, lymph node involvement, and treatment modality failed to reach significance in both univariate and multivariate analysis.ConclusionFIGO stage was a prognostic factor impacting survival—both overall survival and disease-free survival. Age at diagnosis, tumor histology (pure or mixed), tumor size, depth of stromal invasion, lymph node involvement, and treatment modality did not have an impact on overall survival.

Transformation from EGFR/PTEN co‐mutated lung adenocarcinoma to small cell carcinoma in lymph node metastasis

2020 ◽  
Vol 70 (5) ◽  
pp. 295-299
Author(s):  
Takuo Hayashi ◽  
Kazuya Takamochi ◽  
Shinji Kohsaka ◽  
Satsuki Kishikawa ◽  
Yoshiyuki Suehara ◽  
...  
Keyword(s):  
Lymph Node ◽  
Lymph Node Metastasis ◽  
Lung Adenocarcinoma ◽  
Cell Carcinoma ◽  
Small Cell Carcinoma ◽  
Small Cell ◽  
Node Metastasis

scholarly journals Complete Response of Recurrent Small Cell Carcinoma of the Uterine Cervix to Paclitaxel, Carboplatin, and Bevacizumab Combination Therapy

2020 ◽  
Vol 13 (1) ◽  
pp. 373-378 ◽  
Author(s):  
Yuri Nakao ◽  
Satoshi Tamauchi ◽  
Nobuhisa Yoshikawa ◽  
Shiro Suzuki ◽  
Hiroaki Kajiyama ◽  
...  
Keyword(s):  
Lymph Node ◽  
Combination Therapy ◽  
Cell Carcinoma ◽  
Small Cell Carcinoma ◽  
Uterine Cervix ◽  
Posterior Wall ◽  
Complete Response ◽  
Uterine Sarcoma ◽  
Small Cell ◽  
Lymph Node Sampling

We report a case of recurrent small cell carcinoma of the uterine cervix that showed a complete response to paclitaxel, carboplatin, and bevacizumab (TC + Bev) combination therapy. Small cell carcinoma of the uterine cervix is extremely rare, with an incidence of only 1.3% in Japan, and a poor outcome. The patient was a 62-year-old woman with a chief complaint of irregular vaginal bleeding. Magnetic resonance imaging showed a 10-cm irregular mass from the uterine corpus’s posterior wall to the cervix. Abdominal total hysterectomy, bilateral salpingo-oophorectomy, and pelvic lymph node sampling were performed for suspected uterine sarcoma. Histopathological findings revealed small cell carcinoma with lymph node metastasis. Although 6 cycles of etoposide + cisplatin were performed, para-aortic lymph node recurrence was found 3 months after chemotherapy. Subsequently, the patient received 8 cycles of TC + Bev, which eliminated the metastases. The patient is currently alive at 24 months.

scholarly journals KNOCK KNOCK, HU'S THERE? POSITIVE ANTI-HU ANTIBODY IN EXTRAPULMONARY SMALL CELL CARCINOMA OF LYMPH NODE

CHEST Journal ◽  
2019 ◽  
Vol 156 (4) ◽  
pp. A1382-A1383
Author(s):  
Ziqin Ng ◽  
Sharlene Ho ◽  
HUIJIA WANG ◽  
Caroline Choong ◽  
Chuen Peng Lee ◽  
...  
Keyword(s):  
Lymph Node ◽  
Cell Carcinoma ◽  
Small Cell Carcinoma ◽  
Small Cell ◽  
Extrapulmonary Small Cell Carcinoma
Sign in / Sign up

Export Citation Format

Share Document